Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Broad neutralization of SARS-related viruses by human monoclonal antibodies
Anna Z. Wec, Daniel Wrapp, Andrew S. Herbert, et al.
Science (2020) Vol. 369, Iss. 6504, pp. 731-736
Open Access | Times Cited: 603

Showing 1-25 of 603 citing articles:

Adaptive immunity to SARS-CoV-2 and COVID-19
Alessandro Sette, Shane Crotty
Cell (2021) Vol. 184, Iss. 4, pp. 861-880
Open Access | Times Cited: 1749
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Evan J. Anderson, Nadine Rouphael, Alicia T. Widge, et al.
New England Journal of Medicine (2020) Vol. 383, Iss. 25, pp. 2427-2438
Open Access | Times Cited: 1452
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Luca Piccoli, Young‐Jun Park, M. Alejandra Tortorici, et al.
Cell (2020) Vol. 183, Iss. 4, pp. 1024-1042.e21
Open Access | Times Cited: 1438
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Yiska Weisblum, Fabian Schmidt, Fengwen Zhang, et al.
eLife (2020) Vol. 9
Open Access | Times Cited: 1415
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans
José Mateus, Alba Grifoni, Alison Tarke, et al.
Science (2020) Vol. 370, Iss. 6512, pp. 89-94
Open Access | Times Cited: 1189
Potently neutralizing and protective human antibodies against SARS-CoV-2
Seth J. Zost, Pavlo Gilchuk, James Brett Case, et al.
Nature (2020) Vol. 584, Iss. 7821, pp. 443-449
Open Access | Times Cited: 1107
Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape Antibody Recognition
Allison J. Greaney, Tyler N. Starr, Pavlo Gilchuk, et al.
Cell Host & Microbe (2020) Vol. 29, Iss. 1, pp. 44-57.e9
Open Access | Times Cited: 1062
Viral targets for vaccines against COVID-19
Lianpan Dai, George F. Gao
Nature reviews. Immunology (2020) Vol. 21, Iss. 2, pp. 73-82
Open Access | Times Cited: 1050
IgA dominates the early neutralizing antibody response to SARS-CoV-2
Delphine Sterlin, Alexis Mathian, Makoto Miyara, et al.
Science Translational Medicine (2020) Vol. 13, Iss. 577
Open Access | Times Cited: 1007
The biological and clinical significance of emerging SARS-CoV-2 variants
Kaiming Tao, Philip L. Tzou, Janin Nouhin, et al.
Nature Reviews Genetics (2021) Vol. 22, Iss. 12, pp. 757-773
Open Access | Times Cited: 976
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
Matthew McCallum, Anna De Marco, Florian A. Lempp, et al.
Cell (2021) Vol. 184, Iss. 9, pp. 2332-2347.e16
Open Access | Times Cited: 936
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity
H. J. Yang, Wei Wang, Zimin Chen, et al.
Nature (2020) Vol. 586, Iss. 7830, pp. 572-577
Open Access | Times Cited: 755
COVID-19-neutralizing antibodies predict disease severity and survival
Wilfredo F. García-Beltrán, Evan C. Lam, Michael G. Astudillo, et al.
Cell (2020) Vol. 184, Iss. 2, pp. 476-488.e11
Open Access | Times Cited: 711
Structural basis of a shared antibody response to SARS-CoV-2
Meng Yuan, Hejun Liu, Nicholas C. Wu, et al.
Science (2020) Vol. 369, Iss. 6507, pp. 1119-1123
Open Access | Times Cited: 628
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Emma C. Thomson, Laura E. Rosen, James G. Shepherd, et al.
Cell (2021) Vol. 184, Iss. 5, pp. 1171-1187.e20
Open Access | Times Cited: 623
Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
Kui K. Chan, Danielle E. Dorosky, Preeti Sharma, et al.
Science (2020) Vol. 369, Iss. 6508, pp. 1261-1265
Open Access | Times Cited: 601
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Fabian Schmidt, Yiska Weisblum, Frauke Muecksch, et al.
The Journal of Experimental Medicine (2020) Vol. 217, Iss. 11
Open Access | Times Cited: 572
Immunity, endothelial injury and complement-induced coagulopathy in COVID-19
Luca Perico, Ariela Benigni, Federica Casiraghi, et al.
Nature Reviews Nephrology (2020) Vol. 17, Iss. 1, pp. 46-64
Open Access | Times Cited: 561
A systematic review of SARS-CoV-2 vaccine candidates
Yetian Dong, Tong Dai, Yujun Wei, et al.
Signal Transduction and Targeted Therapy (2020) Vol. 5, Iss. 1
Open Access | Times Cited: 538
Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein
Seth J. Zost, Pavlo Gilchuk, Rita E. Chen, et al.
Nature Medicine (2020) Vol. 26, Iss. 9, pp. 1422-1427
Open Access | Times Cited: 504
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
Matthew McCallum, Nadine Czudnochowski, Laura E. Rosen, et al.
Science (2022) Vol. 375, Iss. 6583, pp. 864-868
Open Access | Times Cited: 501
Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2
Yufei Xiang, Sham Nambulli, Zhengyun Xiao, et al.
Science (2020) Vol. 370, Iss. 6523, pp. 1479-1484
Open Access | Times Cited: 402
Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies
Allison J. Greaney, Tyler N. Starr, Christopher O. Barnes, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 402
Structural biology of SARS-CoV-2 and implications for therapeutic development
Haitao Yang, Zihe Rao
Nature Reviews Microbiology (2021) Vol. 19, Iss. 11, pp. 685-700
Open Access | Times Cited: 399
Longitudinal Isolation of Potent Near-Germline SARS-CoV-2-Neutralizing Antibodies from COVID-19 Patients
Christoph Kreer, Matthias Zehner, Timm Weber, et al.
Cell (2020) Vol. 182, Iss. 4, pp. 843-854.e12
Open Access | Times Cited: 382
Page 1 - Next Page

Scroll to top